Allogene Therapeutics collaborates with Cellectis

Allogene Therapeutics will assume the strategic collaboration and license agreement that Pfizer Inc. (NYSE: PFE) had with Cellectis (Nasdaq: CLLS) to develop "off-the-shelf" CAR T immunotherapies for oncology. Shares of Cellectis leaped $7.80 to close at $38.53 while Pfizer stock rose 63 cents to close at $35.68.